

**EUROPEAN DISCOVERY FOR SOLIDARITY: AN ADAPTIVE PANDEMIC AND
EMERGING INFECTION PLATFORM TRIAL
THE EU-SOLIDACT TRIAL**

**PROCEDURE FOR TRANSFER OF PATIENT TO A NEW HOSPITAL DURING THE
TRIAL**

Name:	Marius Trøseid	Role:	Chief Investigator
Signature:		Date:	03-09-2021
Reviewed by:			
Name:	Thale D.J.H. Patrick-Brown	Role:	Project Coordinator
Signature:		Date:	03-09-2021

**VERSION 1.0
DATE: 03-09-2021**

1 TRANSFER TO ANOTHER ACTIVE STUDY SITE

- The study medication should be sent with the patient to the new study site, with information on time for next dose and total number of doses remaining
- If the patient has been biobanked and the new study site agrees to continue biobanking for EU-SolidAct, kits for biobanking should also be sent with the patient to the new study site, with information on time point for next biobank procedures.
- Access to eCRF must be transferred to the new site by sending a request, including the transfer form, by email to solidact.inserm@iplesp.upmc.fr. Complete as much of the eCRF as possible before transfer as the original site will lose access to eCRF.
- After the end of hospitalisation at the new site, eCRF access must be transferred back to the original site by sending an updated transfer form by email to solidact.inserm@iplesp.upmc.fr.

- The original site is responsible for following up with the patient after discharge, up to D91 for the patient, in order to register the remaining visits (D15, D29, D61, where applicable), and to finalise of the eCRF.

2 TRANSFER TO A NON-STUDY SITE

- Study medication and biobanking should be discontinued if the patient is transferred to a non-study site.
- A discharge visit should be undertaken wherein registration of WHO score, concomitant medication as well as location after discharge should be noted. For location after discharge, select No. 6 “Long-term acute care hospital” unless otherwise indicated.
- The original site is responsible for following up with the patient after discharge, up to Day 91 for the patient, in order to register the remaining visits (D15, D29, D61, where applicable), and to finalise of the eCRF.